Therapeutic Area

Antiepileptic

Therapeutic area intelligence for Antiepileptic with 10 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 10
Catalysts: 0
Companies: 5

Companies

Aurobindo Pharma →

Glenmark Pharmaceuticals →

Lupin →

Mankind Pharma →

Mylan →

Assets

Recent signals(10)

RegulatoryJune 21, 2026

FDA Accepts Supplement for Levetiracetam ANDA204754 by Aiping Pharm

The FDA has accepted a supplemental application for ANDA204754, a generic version of levetiracetam, from Aiping Pharm.

CompetitiveJune 19, 2026

Lupin's Divalproex Sodium ANDA209286 Receives Abbreviated Approval

Lupin has received an abbreviated approval for its ANDA209286 application for Divalproex Sodium.

RegulatoryJune 19, 2026

FDA Grants AP Status for Divalproex Sodium ANDA217358 by Mankind Pharma

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Divalproex Sodium submitted by Mankind Pharma.

StrategyJune 18, 2026

FDA Grants Approval for Lacosamide ANDA217596

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 217596 for lacosamide.

CompetitiveJune 18, 2026

FDA Submission Update for Topiramate by Aiping Pharm Inc.

Aiping Pharm Inc. has submitted an application (ANDA078499) for Topiramate with a standard review priority.

StrategyJune 18, 2026

FDA Approval Update for Divalproex Sodium by Mylan

The FDA has granted an Abbreviated New Drug Application (ANDA) approval for Divalproex Sodium submitted by Mylan.

StrategyJune 18, 2026

FDA Grants Abbreviated Approval for Divalproex Sodium by Unichem

The FDA has granted an abbreviated approval for Divalproex Sodium under application ANDA214643 submitted by Unichem.

RegulatoryJune 7, 2026

Glenmark Pharmaceuticals submits supplemental application for Lamotrigine

Glenmark Pharmaceuticals has submitted a supplemental application for Lamotrigine under ANDA090169, currently under standard review.

StrategyJune 6, 2026

Aurobindo Pharma's Lamotrigine ANDA Submission Receives AP Status

Aurobindo Pharma's ANDA078956 for Lamotrigine has received an Abbreviated Approval (AP) status from the FDA.

RegulatoryJune 6, 2026

FDA Approves Supplement for Levetiracetam by Chartwell RX

The FDA has approved a supplemental application for levetiracetam submitted by Chartwell RX.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.